JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis

• Main Authors: Ristić Slobodan, Radojković Milica, Kostić Tatjana, Spasovski Vesna, Pavlović Sonja, Čemerikić-Martinović Vesna
• Format: Article
• Language: English
• Published: Serbian Medical Society 2015-01-01
• Series: Srpski Arhiv za Celokupno Lekarstvo
• Subjects: chronic lymphocytic leukemia; myelofibrosis; JAK2V617F mutation
• Online Access: http://www.doiserbia.nb.rs/img/doi/0370-8179/2015/0370-81791512739R.pdf

Introduction. Secondary malignancies, particularly solid tumors, are common in patients with chronic lymphocytic leukemia (CLL), but association of myeloproliferative neoplasms and chronic lymphocytic leukemia in the same patient is very rare. Case Outline. We report of a 67-year-old man with B-cell chronic lymphoid leukemia (B-CLL) who developed primary myelofibrosis (PMF) nine years after initial diagnosis. Patient received alkylation agents and purine analogue, which can be a predisposing factor for the development of myeloproliferative neoplasms. JAK2V617F mutation was not present initially at the time of CLL diagnosis, but was found after nine years when PMF occurred, which indicates that B-CLL and PMF represent two separate clonal origin neoplasms. Conclusion. Pathogenic mechanisms for the development of myeloproliferative and lymphoproliferative neoplasms in the same patient are unknown. Further research is needed to determine whether these malignancies originate from two different cell clones or arise from the same pluripotent hematopoietic stem cell. [Projekat Ministarstva nauke Republike Srbije, br. III 41004]